<i>Bifidobacterium longum</i> extract exerts pro‐differentiating effects on human epidermal keratinocytes, in vitro

Szöllősi, Attila Gábor; Guéniche, Audrey; Jammayrac, Odette; Szabó-Papp, Judit; Blanchard, Carine; Vasas, Nikolett; Andrási, Mónika; Juhász, István; Breton, Lionel; Bı́ró, Tamás

doi:10.1111/exd.13130

Cited by 16 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of topical probiotics may have special subclinical significance, for example to improve skin defense with probiotic‐containing cosmeceuticals. It has been reported that B. longum strains exert pro‐differentiating and pro‐regenerating effects on primary human epidermal keratinocytes . However, topical applications of probiotics can create challenges, not only because of the problem of proper formulation, but also the environmental conditions of the skin that may prevent colonization by the probiotic .…”

Section: Discussionmentioning

confidence: 99%

“…It has been reported that B. longum strains exert pro-differentiating and pro-regenerating effects on primary human epidermal keratinocytes. [111] However, topical applications of probiotics can create challenges, not only because of the problem of proper formulation, but also the environmental conditions of the skin that may prevent colonization by the probiotic. [113] It seems probable though that using the most suitable oral probiotic strain in combination with topical probiotics and/or prebiotics might help in the individualized design of treatment of skin disorders.…”

Section: Con Clus Ionsmentioning

confidence: 99%

See 1 more Smart Citation

Targeting the gut‐skin axis—Probiotics as new tools for skin disorder management?

Szántó

Dózsa

Antal

et al. 2019

Experimental Dermatology

125

View full text Add to dashboard Cite

The existence of a gut-skin axis is supported by increasing evidence, but its translational potential is not widely recognized. Studies linked inflammatory skin diseases to an imbalanced gut microbiome; hence, the modulation of the gut microbiota to improve skin condition seems to be a feasible approach. Today, there is a growing interest in natural products as alternatives to synthetic drugs. In this respect, oral probiotics could be a simple, safe and cheap modality in the therapeutic management of skin inflammation. Unfortunately, very few studies have looked into how probiotic supplementation influences inflammatory skin disorders. The result, though promising, are difficult to implement in clinical practice due to the heterogeneity of the applied supplemental regimen in the different studies. In this Viewpoint, we aim to encourage the conduction of more research in that direction to explore unambiguously the therapeutic potential of oral probiotics in dermatology. We focus on the most common inflammatory skin diseases (atopic dermatitis, psoriasis, rosacea, acne vulgaris) with an associated gut dysbiosis, but we also discuss some less common, but very serious skin pathologies (eg erythema nodosum, pyoderma gangrenosum, hidradenitis suppurativa) that are possibly linked to a disturbed gut flora composition. We dissect the possible mechanisms along the gut-skin axis and highlight novel points where probiotics could interfere in this communication in the diseased state.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Con Clus Ionsmentioning

confidence: 99%

Targeting the gut‐skin axis—Probiotics as new tools for skin disorder management?

Szántó

Dózsa

Antal

et al. 2019

Experimental Dermatology

125

View full text Add to dashboard Cite

show abstract

“…Since NHEK are frequently used as model cells to study the functions of the skin cell barrier (16)(17)(18)(19)(20), they were also used in the present study. In the present study, it was firstly observed that exogenous gefitinib was able to damage the cell barrier function via inhibiting the EGFR, Src and STAT3 pathways, accompanied by regulating the expression of cLdN proteins.…”

Section: Discussionmentioning

confidence: 99%

EGFR inhibitor gefitinib regulates barrier function in human epidermal keratinocytes via the modulation of the expression of claudins

Fang

Wang

et al. 2018

Int J Mol Med

View full text Add to dashboard Cite

Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been frequently used in targeted therapy for lung cancer. However, the widespread use of gefitinib in targeted therapy for patients with lung cancer is hampered by its common skin toxicities. The present study aimed to investigate the mechanisms underlying the skin toxicities of gefitinib. Normal human epidermal keratinocytes (NHEKs) treated with gefitinib were used for a series of in vitro assays, including MTT, reverse transcription-quantitative polymerase chain reaction, western blot analysis, immunohistochemistry and transepithelial electrical resistance and paracellular permeability detection. In the present study, it was determined that the skin toxicities of gefitinib may be due to claudin (cLdN)1 and cLdN4 downregulation and cLdN2 upregulation in NHEKs. Additionally, Src and signal transducer and activator of transcription 3 pathways were involved in gefitinib-induced barrier function disruption in NHEKs. In conclusion, the present study may provide novel insights for improving skin toxicity of gefitinib in patients with lung cancer.

show abstract

“…The use of topical probiotics may have special subclinical significance, for example, to improve skin defense with probiotic-containing cosmeceuticals. It has been reported that B. longum strains exert pro-differentiating, as well as and proregenerating, effects on primary human epidermal keratinocytes [68]. Thus, using the most suitable oral probiotic strain in combination with topical probiotics and/or prebiotics might help in the personalized treatment of skin disorders.…”

Section: Therapeutic Implementsmentioning

confidence: 99%

Skin and Gut Microbiota in Psoriasis: A Systematic Review

Rungjang¹,

Meephansan²,

Thio³

2021

Human Microbiome

View full text Add to dashboard Cite

Paying attention to a microbial approach may lead to improvements in diagnosis, treatment, prevention, and prognosis of psoriasis. A systematic review was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines searching strategy to identify the pattern of the microbiome and the association of skin and gut microbiota with psoriasis, including the factors that may affect the results of the microbial study. In total, 16 studies were included in this systematic review. Ten studies investigated the skin microbiome, of which six studies were cross-sectional and four studies were prospective studies. Six studies investigated the gut microbiome, including five cross-sectional studies and one prospective study. The understanding of the relationship between microbiota and psoriasis may lead to diagnostics and treatment improvements. Currently, there is a slight consensus on some specific features that define psoriasis. However, no specific taxa have been identified as biomarkers of the disease, even from large-scale cohort studies. Thus, future cohort studies with standardized methodologies and proof-of-concept investigations in animal models may uncover the role of microbiota and the microbial pathways in psoriasis.

show abstract

Bifidobacterium longum extract exerts pro‐differentiating effects on human epidermal keratinocytes, in vitro

Cited by 16 publications

References 8 publications

Targeting the gut‐skin axis—Probiotics as new tools for skin disorder management?

Targeting the gut‐skin axis—Probiotics as new tools for skin disorder management?

EGFR inhibitor gefitinib regulates barrier function in human epidermal keratinocytes via the modulation of the expression of claudins

Skin and Gut Microbiota in Psoriasis: A Systematic Review

Contact Info

Product

Resources

About